##### 



Exhibit 99.1




|Developing clinical stage small molecule
therapeutics to treat hormonal and
reproductive system disorders
|---------------------------------------------------------------------------------------------------------



---



##### 



|Forward-Looking Statements

This presentation contains forward-looking statements and information
regarding the future performance and actions of Repros Therapeutics Inc.
(RPRX) that involve risks and uncertainties that could cause actual results
and actions to differ materially.  These risks include those discussed in this
presentation and others that can be found in Repros' Form 10-K for the year
ended December 31, 2006 and in the Form 10-Q's for the quarters ended
March 31, June 30 and September 30, 2007, which contain additional
important risk factors that could cause actual results to differ from its current
expectations and from the forward-looking statements made in this
presentation. RPRX is providing this information as of this date and does not
undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future events or
otherwise.  No forward-looking statement can be guaranteed and actual
results may differ materially from those we project.  The results of initial
clinical trials do not necessarily predict the results of later-stage clinical
trials.  RPRX cannot guarantee that data collected from clinical trials of any
product candidate will be sufficient to support FDA or other regulatory
approval.
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Repros Strategy

Focus on small molecule therapeutics for reproductive system disorders
that exhibit significant market potential and that are currently
underserved

Develop highly differentiable drugs

Proellex for the treatment of uterine fibroids and endometriosis

Androxal for the treatment of endocrine disorders

Fertility preservation/improvement in treatment of 2^ hypogonadism

Treatment of Metabolic Syndrome in men with idiopathic adult onset
hypogonadotropic hypogonadism

Outsource clinical development activities

"lean," fiscally responsible company with active board

Seek maximum return on shareholder investment through corporate
transaction
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Proellex(tm)
|------------



---



##### 



|Proellex Product Development
Timeline
        H1'04    H2'04    H1'05    H2'05    H1'06    H2'06    H1'07    H2'07    H1'08    H2'08    H1'09    H2'09    H1'10    H2'10
    Cummulative Spending


Euro PHI/II UF

PreClin Tox

US PH II/III UF Study.

US UF Extension Study

Carcinogenicity Studies

US PH III Anemia

Euro Endo Phase II

US Endo

 Phase II

US PH III  UF

US UF Open Label Safety

US  Extension Study

NDA

NDA

NDA

UF Pre-IND Mtg

UF IND

Endo Pre-IND Mtg

UF End of PHII Mtg

Nov. 30, 2007

Endo End of PHIII Mtg

US PH III  Endo

QT Interval

Anemia

Fibroid Symptoms

Endometriosis

Symptoms
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Proellex Overview

New class of selective progesterone receptor modulator (SPRM)

No antiglucocorticoid activity

Potential indications:  uterine fibroids, endometriosis, breast cancer and
HRT

Potential significant advantages over existing GnRHa therapies

No loss of bone mineral density in clinical trials

No chronic drug treatments available

Composition of matter patent issued in the US

Patent life to 2017

Potential for Hatch-Waxman extension

Potential use applications with life to 2027

Licensed from the NIH

44 compounds included in license

Worldwide exclusive rights
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|How Proellex Works

Blocks hypothalamus /
pituitary axis

Shuts down hormonal
secretions

Long-term side effects
including bone loss



Selectively blocks
progesterone activity

Allows tonic hormone
secretions

Alleviates negative side
effects of GnRHa

Potential for chronic use

GnRHa

Proellex

Hypothalamus

Pituitary

Endometrial

&

Uterine
Tissue
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Uterine Fibroids

Benign, monoclonal, hormone
sensitive, smooth muscle tumors of the
uterus

Most common tumor of the female
reproductive tract

Heavy bleeding / anemia

Abdominal pressure / pain / urinary
frequency

Affect 20-77% of women age 35 - 55

600,000 hysterectomies conducted
annually

annually
annually
annually
annually
annually
annually
annually
annually
annually
annually
annually

Courtesy of Jay Goldberg, MD, MSCP

Director, Jefferson Fibroid Center

Director, Division of General OB/GYN

Jefferson Medical College, Philadelphia, PA
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Uterine Fibroids

Large Underserved Market

Conservative Estimate, 15% of women of
reproductive age with symptomatic uterine
fibroids

174,716,000 women in US, Japan, France, Germany, Italy,
Spain, UK of reproductive age

Potentially 26,000,000 women with symptomatic uterine fibroids

300,000 women in US undergo hysterectomy for fibroids every
year (severe cases of fibroids)

Extrapolates to 700,000 severe cases currently requiring surgery
or radical treatment in large market countries

Mean age of women seeking UF treatment, 39

Potential years on therapy, 10

Uterine Fibroids regress when a woman reaches menopause
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Large Untapped Pharmaceutical
Opportunity


Assume only the 700,000 women per
year requiring surgery would potentially
seek a drug treatment

Assume the drug would be used for the
10 years  between the ages of 39 and 49
to avoid surgery and reach menopause
(7,000,000 patients potentially using
drug per year from this group only)

Assume only 25% of severe case women
would opt for a pharmaceutical
intervention

Assume the annual price of the drug into
the market is $1000/patient

Annual Proellex sales for the treatment
of Uterine Fibroids in Major Market
countries



$1,750,000,000/yr
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Key Symptom Driving Women to Seek Therapy

for Uterine Fibroids

Excessive Menstrual Bleeding
        Spotting    Light    Moderate    Heavy
    12.5    0.8    0.4    2.2    0.4
    25    1.8    2.2    0.4    0.4
    50    3.6    0.4    0.6    0.4
    Lupron    8.6    2.4    1.6    2.4
    Placebo    13.4    7.6    8.6    2.2


European Pilot Study

(n=30)
        BL    Mo 1    Mo 2    Mo 3
    Placebo    113.5    91    83    69
    Proellex 12.5 mg    133.5    1    1    1
    Proellex 25 mg    120    1    1    1


P<0.05

US Phase IIb

(n=127)

P<0.0001

Menorrhagia=PBAC>80

Basis for Commencement of US Phase III Studies
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Proellex Produces Significant Clinical Benefit
Resulting in Substantially Asymptomatic Uterine
Fibroids
                Symptom Severity    Concern
    Placebo            40.1    61.6
    12.5 mg Proellex            17.4    83.6
    25 mg Proellex            14.9    86.6
    Normal            22.5    84


UFSQOL Uterine Fibroid Symptom Survey


p vs placebo

< 0.0001 for both

doses

p vs placebo

< 0.005 for both

doses

Spies et al, Obstetrics & Gynecology, vol. 99, No. 2, February 2002

Higher Score = Worse

Higher Score = Better

US Phase IIb (n=127)
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Basis for New IND for Proellex for the Pre-Surgical
Treatment of Anemia Associated with Uterine
Fibroids
        BL    Mo 1    Mo 2    Mo 3
    Placebo    10.6    10.6    10.5    10.2
    Proellex 12.5 mg    10.2    10.3    12    12.4
    Proellex 25 mg    9.9    10.8    11.9    12.1


Median Hemoglobin g/DL

12.5 and 25 mg

p < 0.002 vs Pl

1 g increase = ~1 pint of blood

Results from US Phase IIb Study

Roughly 40% of women seeking therapy for fibroids are anemic

and therefore surgical risks

Estimated $120-160 million annual market in major countries
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Proellex Experience to Date Suggests
Manageable Side Effect Profile


Most common drug related side effects

Amenorrhea: 78.6% (no longer considered a side effect)

Hot Flashes: 16.7%

With a small data base, differences in low incidence events have to
be interpreted with caution

No tendency towards bone loss unlike GnRHa "Gold Standard"

No tendency toward endometrial hyperplasia with increasing doses
of Proellex

Amenorrhea, an expected pharmacological effect of Proellex, is
dose dependent

Excluding amenorrhea & hot flashes, the incidence and severity of
AEs was similar in all dose groups, and similarly distributed between
mild, moderate and severe
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Definition: the presence

of epithelial and stromal
endometrial cells outside

of the uterine cavity

Complaints of infertility or
pregnancy loss

Pelvic pain/back pain

Dyspareunia (pain during sex)

Dysmenorrhea (menstrual cycle
cramps)


Endometriosis

5% of women of reproductive
age

Estimated that 25 - 40% (2 - 4
million) of infertility cases may
be due to endometriosis

71 - 87% in women with chronic
pelvic pain

53% of teenagers with
dysmenorrhea

Many women have it without the
diagnosis

Unmet medical need

Oc's, Lupron, Danazol

Laparascopic procedures

High recurrence rate after
treatment


Courtesy of  Bruce A. Lessey, MD, PhD

Professor of Obstetrics and Gynecology

University of South Carolina

University of South Carolina
University of South Carolina
University of South Carolina
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Endometriosis

Large Underserved Market

Estimate, 10% of women of reproductive age
with endometriosis

174,716,000 women in US, Japan, France, Germany, Italy,
Spain, UK of reproductive age

Potentially 17,000,000 women with endometriosis

Market for endometriosis drug treatments in 2007 roughly $1.2
billion

Japanese market approximately same size of US market in $
sales

Radical surgery not an option for young women of reproductive
age

GnRHa's "Gold Standard" but limited to not more than 6 month
treatment due to bone loss

Progestin-only-contraceptives most commonly used but with
marginal benefit
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Large Untapped Pharmaceutical
Opportunity

Even though large population of women with endometriosis exists,
poor treatment options and poor diagnosis limits the current market
for endometriosis

Nevertheless $1.2 billion are spent in the major markets

If only 10% of the estimated number of women with endometriosis will
seek treatment for their condition with a truly effective therapy, the
market in the major countries is reflective of 1,700,000 patients

Assume the annual price of the drug into the market is $1000/patient

Annual Proellex sales for the treatment of Endometriosis in Major
Market countries



$1,750,000,000/yr
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Key Symptom Driving Women to Seek Therapy

for Endometriosis

Pelvic Abdominal Pain


Fewer mean days of pain
with 50mg Proellex
(higher percentage of
pain free days than with
Lupron) p< 0.05

Lupron not statistically
different than 12.5mg
and 25mg Proellex dose

% Pain Free Days

As Reported thru Month 6

Results of European Pilot Study (n=40) & Basis of Current IND

Range of patient

experiences

50 mg dose yields range of 88-100%

Pain free days
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|General Concern for Treatment with Progesterone Receptor Modulators

Endometrial Thickening/Hyperplasia?

Dosing on Day 5
|-------------------------------------------------------------------------------------------------------------------------



---



##### 



|Proellex Effects on Endometrial
Thickness
            Month 3
    12.5mg        9
    25mg        4
    Placebo        6


US Phase II/III Study
        0    3    6
    Lupron    5.3    3.1    3.5
    12.5mg    9.8    11.8    20.9
    25mg    8.9    12.9    16.6
    50mg    11    9.2    14.5


FDA Recommended Thickness Cutoff

Statistically Significant Difference In Month 6

Thicknesses
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Unopposed estrogen effect vs Proellex

Proliferative

Disordered

Proliferative

Benign

Endometrial

Hyperplasia

Estrogen
over Time

cysts

remodeling

variable density

Mutter et al, 2007

12.5mg Proellex
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|"Off Drug Interval" Treatment Strategy

4 Month Dosing Cycle

4 Month Dosing Cycle

4 Month Dosing Cycle

Off Drug Interval to allow for:

Menses

Refresh the endometrium

Experience to date suggests

 menses returns in 25-35 days

Return of symptoms


Continue as needed

Concept has been accepted by the FDA

as noted in End of Phase II meeting minutes
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Summary of FDA Meetings Held to
Date for Proellex

FDA willing to consider development of drug for several uterine fibroid indications

Preoperative treatment

Treatment of perimenopausal women with fibroids

Chronic treatment of fibroids to avoid surgery

New IND for Anemia to be submitted in Jan'08

Repros plans to commence double-blind, placebo controlled

Phase 3 trials in Q1'08

Treatment of Symptoms Associated with Uterine Fibroids (2 trials)

Treatment of Anemia in Patients that are surgical risks for fibroid removal (2 trials)

~75 patients per trial

Ongoing Phase II endometriosis study (n=75)

Plan interim analysis late Q2'08

Open label extension studies as required to satisfy safety data base

400 patient 2-cycle study with holiday until symptoms return (25mg or 50mg Proellex )

500 patient 3-cycle study with holiday until menses returns to satisfy FDA need for 200
patients for one year of dosing (Rate limiting step for chronic treatment NDA)

Protocols to submitted to FDA for input mid Q1'08

Pooled safety data base with endometriosis program to achieve 1500 patients
exposed to drug at any dose for any interval
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Androxal
|--------



---



##### 



|Androxal

Trans isomer of clomiphene citrate

Cis isomer opposes action and has increased side effect risk

Antiestrogen that normalizes pituitary responsiveness in 2^ hypogonadal men

Highly statistically significant results in 6 month Phase III study showing
restoration of pituitary responsiveness resulting in normalization of testicular
function and testosterone levels

Non-inferior to Androgel for all parameters measured

No agreement with FDA re endpoints for pivotal trial

No agreement with FDA re endpoints for pivotal trial
No agreement with FDA re endpoints for pivotal trial
No agreement with FDA re endpoints for pivotal trial
No agreement with FDA re endpoints for pivotal trial
No agreement with FDA re endpoints for pivotal trial
No agreement with FDA re endpoints for pivotal trial
No agreement with FDA re endpoints for pivotal trial
No agreement with FDA re endpoints for pivotal trial
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Testosterone Market
        6/04-6/05
    US    461
    Rest of World    140


2004 Figures
        2003    2004    2005 est.
    Total Market    399    459    486
    Androgel    275    308    326
    Androderm    50    57    55
    Testim    13    31    43
    Testosterone Inj.    31    31    24


A U.S. Phenomenon
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Androxal Phase 3 Trial

Enrollment completed in Nov. '06

N = 194 men at 18 US sites

Patient testosterone levels < 300 ^g/dl

FDA agreement re: safety not efficacy

Randomized into 4 arms: 2 doses of Androxal, placebo, and
Androgel

6 mo study with efficacy assessment at 3 mo with roll over to

12 mo open-label extension

Efficacy: testosterone levels, libido, distress

Safety: pituitary effects, average testosterone, sperm function

Status: 194 men enrolled, top-line data anticipated June 2007

Open label extension ongoing; data expected June 2008
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Androxal Type C FDA Meeting: Oct.
15,2007

Outcome
        <300    300-400    400-800    >800
    25 mg    17.1    19.5    53.6    9.8
    12.5 mg    27.5    25    45    2.5
    Androgel    43.2    19.5    34.1    2.4
    Placebo    72.5    22.5    0    0

        Month 6
    Placebo    267.8
    Androgel    370.9
    12.5 mg Androxal    402.9
    25 mg Androxal    508.7


P vs Androgel = 0.009


FDA made the following observations

T as an endpoint for non testosterone therapy is unacceptable

Avoiding worsening of LH secretions in secondary hypogonadal

 men unacceptable endpoint

No known quality of life endpoints acceptable

Unlike testosterone Androxal would not be considered a controlled

 substance

FDA willing to consider fertility effects of Androxal

FDA willing to consider proposal for treatment of metabolic syndrome
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Androxal Regulatory Strategy

Conduct Phase IIb study in men with AIHH
and Metabolic Syndrome

Conduct Phase IIb study in hypogonadal
men of reproductive age showing
improvement or maintenance of
fertility/sperm status

No primary Quality of Life endpoints
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Impact of Hypogonadism on Insulin
Sensitivity and Metabolic Syndrome
        T<280    T>280
    East    4.3    7.4


American Heart Association definition
of Metabolic Syndrome



Elevated waist circumference, ^ 40"



Triglycerides, ^ 150 mg/dl



Reduced HDL, < 40 mg/dl



Elevated Blood Pressure, ^ 130/85



Elevated Fasting Glucose, ^ 100 mg/dl

P<0.05

T<280 90% Metabolic Syndrome

T>280 29% Metabolic Syndrome

Pitteloud et al, Journal of Clinical Endocrinology & Metabolism 90(5):2636-2641

"In men, low T levels predisposes to central obesity and predicts the development of both

the metabolic syndrome and DM2."
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Change in Serum Glucose

Subset of Men BMI>26, Glucose >99

(+50% patients studied)
        0    1    2    3
    Androxal Pooled    0    -15    -16    -23


No significant change in Placebo or Androgel arms

Significant mean change in Androxal arm p<0.01

0

1

2

3
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Metabolic Syndrome Clinical Strategy

Submit white paper to FDA

FDA  to determine if IND to be moved to
endocrine division

Commence Phase IIb study in academic
setting to elucidate Androxal effects on
metabolic syndrome as soon as practical

Submit protocol for Phase III study once
Phase IIb is complete
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Impact of Androxal on Male Fertility
        Baseline    6 Months
     Androgel    5.42    1.1
    12.5 mg Androxal    7.02    9.1
    25 mg Androxal    6.4    11.8



Comparison of Means p=0.011

Comparison of Median p=0.0045

32% of men in study under age of 50

Exogenous testosterone suppresses pituitary secretion of FSH

FSH required for stimulation of sertoli cell spermatogenisis

Suppressed FSH suppresses spermatogenisis as evidenced

 by reduction in testicular size
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Fertility Clinical Strategy

Submit white paper to FDA

Commence Phase IIb study in academic
setting to elucidate Androxal effects on fertility

Submit protocol for Phase III study once
Phase IIb is complete
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Androxal Product Development
Timeline
        H1'04    H2'04    H1'05    H2'05    H1'06    H2'06    H1'07    H2'07    H1'08    H2'08    H1'09    H2'09    H1'10    H2'10
    Cummulative Spending


US PHI/II

PreClin Tox

US PH III Safety Study.

US  Extension Study

Carcinogenicity Studies

US PH Ib Fertility

US PH IIb

 metabolism

 Phase III Studies

End of PII Mtg

 IND

Type C Mtg

Oct. 15, 2007

Attempt at SPA

NDA
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Repros Fundamentals

Shares Outstanding

12,774,904 (all common, no warrants)

2005 Cash Burn

$7,391,000

2006 Cash Burn

$14,195,000 (no debt)

Burn 2007

~$14,500,000

Unaudited Cash on 1/6/08 : approximately $25.0million
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Repros Ownership


Filing on 10-27-06

Total Reporting Shares: 5,993,082





HBK Management LLC                      943,400

ProMed Management LLC               843,485

Great Point Partners LLC      721,100

Xmark Opportunity Partners LLC      698,739

Efficacy Capital Ltd            672,528

UBS Securities LLC         628,801

Quogue            605,754

Caxton Associates LLC                      177,505

Barclays Global Investors (CA)          111,424

Joseph Podolski                           100,881

Vanguard Group, Inc                             89,928

Balyasny Asset Management LLC        80,000

Perceptive Advisors LLC        78,127

Morgan Stanley & Co                             78,700

Louis Ploth           32,722

Others (12)         129,988

Filing as of 1-4-08

Total Reporting Shares:~8,071,389





Efficacy Capital Ltd         2,371,013

Orbimed                            1,002,300

Great Point Partners LLC      921,594

Visium Asset Management      860,788

ProMed Management LLC      663,144

Franklin Advisors         486,300

Wall Street Associates      275,000

Dimensional Fund Advisors                257,123

Balyasny Asset Management      220,785

Barclays Global Investors (CA)      167,740

Joseph Podolski                               108,381

DWS Investment GmbH      106,400

Vanguard Group, Inc.                              90,174

Fred Alger Management         88,541

Stoneridge Investment         66,225

AXA Investment Managers,Paris          64,000

AXA Framlington                                   64,000

Millenium Partners            53,297

Seneca Capital            52,000

Alternative Invest. Partners         40,282

Hovan Capital            40,282

Northern Trust            36,303

Louis Ploth            35,717
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Date    Close    Volume
    10/24/2007    0.075796
    10/23/2007    0.2111
    10/22/2007    0.0761
    10/19/2007    0.099
    10/18/2007    0.1058
    10/17/2007    0.2012
    10/16/2007    0.5684
    10/15/2007    0.0367
    10/12/2007    0.061
    10/11/2007    0.1115
    10/10/2007    0.0286
    10/9/2007    0.0544
    10/8/2007    0.0259
    10/5/2007    0.0911
    10/4/2007    0.0907
    10/3/2007    0.1284
    10/2/2007    0.1663
    10/1/2007    0.098
    9/28/2007    0.0431
    9/27/2007    0.0658
    9/26/2007    0.0247
    9/25/2007    0.0733
    9/24/2007    0.0875
    9/21/2007    0.093
    9/20/2007    0.0922
    9/19/2007    0.0181
    9/18/2007    0.0456
    9/17/2007    0.0725
    9/14/2007    0.0626
    9/13/2007    0.1192
    9/12/2007    0.081
    9/11/2007    0.0559
    9/10/2007    0.032
    9/7/2007    0.0627
    9/6/2007    0.0812
    9/5/2007    0.0701
    9/4/2007    0.0601
    8/31/2007    0.0593
    8/30/2007    0.0811
    8/29/2007    0.0975
    8/28/2007    0.1433
    8/27/2007    0.0947
    8/24/2007    0.0765
    8/23/2007    0.0758
    8/22/2007    0.0805
    8/21/2007    0.0412
    8/20/2007    0.0385
    8/17/2007    0.1521
    8/16/2007    0.0996
    8/15/2007    0.0561
    8/14/2007    0.0764
    8/13/2007    0.095
    8/10/2007    0.0815
    8/9/2007    0.1916
    8/8/2007    0.2286
    8/7/2007    0.0669
    8/6/2007    0.0928
    8/3/2007    0.0758
    8/2/2007    0.0496
    8/1/2007    0.0271
    7/31/2007    0.0544
    7/30/2007    0.0868
    7/27/2007    0.0522
    7/26/2007    0.2477
    7/25/2007    0.0607
    7/24/2007    0.0581
    7/23/2007    0.0335
    7/20/2007    0.0511
    7/19/2007    0.0272
    7/18/2007    0.0414
    7/17/2007    0.0198
    7/16/2007    0.0454
    7/13/2007    0.0521
    7/12/2007    0.0612
    7/11/2007    0.0384
    7/10/2007    0.0482
    7/9/2007    0.0423
    7/6/2007    0.0907
    7/5/2007    0.1868
    7/3/2007    0.0555
    7/2/2007    0.1346
    6/29/2007    0.0603
    6/28/2007    0.0984
    6/27/2007    0.0533
    6/26/2007    0.0813
    6/25/2007    0.1003
    6/22/2007    0.0632
    6/21/2007    0.0666
    6/20/2007    0.1636
    6/19/2007    0.1035
    6/18/2007    0.1385
    6/15/2007    0.3249
    6/14/2007    0.0719
    6/13/2007    0.2104
    6/12/2007    0.2223
    6/11/2007    0.0893
    6/8/2007    0.0836
    6/7/2007    0.1552
    6/6/2007    0.1338

Cash

(MM)
    Date    Close
    10/24/2007    12.54
    10/23/2007    12.62
    10/22/2007    12.33
    10/19/2007    12.28
    10/18/2007    12.41
    10/17/2007    12.64
    10/16/2007    12.69
    10/15/2007    10.73
    10/12/2007    10.69
    10/11/2007    10.98
    10/10/2007    10.85
    10/9/2007    10.71
    10/8/2007    11.24
    10/5/2007    11.29
    10/4/2007    11.5
    10/3/2007    11.28
    10/2/2007    11.53
    10/1/2007    11.34
    9/28/2007    11.5
    9/27/2007    11.7
    9/26/2007    11.07
    9/25/2007    11.11
    9/24/2007    11.22
    9/21/2007    10.76
    9/20/2007    10.95
    9/19/2007    10.35
    9/18/2007    10.15
    9/17/2007    10.23
    9/14/2007    10.28
    9/13/2007    10.4
    9/12/2007    10.45
    9/11/2007    10.63
    9/10/2007    10.87
    9/7/2007    10.6
    9/6/2007    10.99
    9/5/2007    11.03
    9/4/2007    11.18
    8/31/2007    10.64
    8/30/2007    10.64
    8/29/2007    10.5
    8/28/2007    10.42
    8/27/2007    11.49
    8/24/2007    11.87
    8/23/2007    12.32
    8/22/2007    12.33
    8/21/2007    12.5
    8/20/2007    12.55
    8/17/2007    12.74
    8/16/2007    12.59
    8/15/2007    12.77
    8/14/2007    12.94
    8/13/2007    13.42
    8/10/2007    13.97
    8/9/2007    14.11
    8/8/2007    13.88
    8/7/2007    13.17
    8/6/2007    12.4
    8/3/2007    12.86
    8/2/2007    13.45
    8/1/2007    13.18
    7/31/2007    13.15
    7/30/2007    13.19
    7/27/2007    13.02
    7/26/2007    12.87
    7/25/2007    12.5
    7/24/2007    12.69
    7/23/2007    13.1
    7/20/2007    13.07
    7/19/2007    13.09
    7/18/2007    13.07
    7/17/2007    13.29
    7/16/2007    13.14
    7/13/2007    13.4
    7/12/2007    13.42
    7/11/2007    13.07
    7/10/2007    12.83
    7/9/2007    12.99
    7/6/2007    12.92
    7/5/2007    12.71
    7/3/2007    12.48
    7/2/2007    12.46
    6/29/2007    12.5
    6/28/2007    12.81
    6/27/2007    12.84
    6/26/2007    12.59
    6/25/2007    12.99
    6/22/2007    12.77
    6/21/2007    12.81
    6/20/2007    12.84
    6/19/2007    12.67
    6/18/2007    13.16
    6/15/2007    12.58
    6/14/2007    13.36
    6/13/2007    13.16
    6/12/2007    14
    6/11/2007    14.93
    6/8/2007    14.56
    6/7/2007    14.03
    6/6/2007    14.34

2004

Repros Performance

2004 - to Date

2005

2006

$8.2                                                       $5.5      $23.9       $21.1      $19.1       $16.8     $12.5      $9.9     $6.7      $35.7  $31.8

2007

2,610,000 Share Follow-on

Net $33 million
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Recent and Upcoming Milestones &
Goals
   ?   4Q06   Report interim U.S. Phase 3 Androxal results
   ?   4Q06   Report interim results from Proellex Phase 1/2 endometriosis trial
   ?   4Q06   Report interim results from Proellex Phase 2/3 fibroid trial
   ?   1Q07   Raise $33 million in public offering
   ?   2Q07   Report top-line Proellex Phase 2/3 fibroid data
   ?   3Q07   Initiate double-blind US Proellex Phase 2 endometriosis trial
   ?   3Q07   Report top-line Phase 3 Androxal data
   ?   1Q08   Initiate Proellex Pivotal Phase 3 fibroid trials (including anemia)
   ?   1Q08   Report on Proellex open-label fibroid trial
   ?   2Q08   Report on Proellex interim results for endometriosis PhII Study
   ?   End '08    Submit Proellex NDA for anemia indication
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Thank you
|---------